Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report)'s stock price gapped up before the market opened on Friday . The stock had previously closed at $12.33, but opened at $13.07. Y-mAbs Therapeutics shares last traded at $12.88, with a volume of 11,538 shares traded.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on YMAB shares. Truist Financial started coverage on shares of Y-mAbs Therapeutics in a research note on Friday. They issued a "buy" rating and a $21.00 target price for the company. HC Wainwright boosted their price objective on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Monday, May 13th. Canaccord Genuity Group raised their price target on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a "buy" rating in a research report on Monday, March 4th. Finally, BMO Capital Markets raised their price objective on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an "outperform" rating in a report on Monday, March 4th. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $17.86.
Get Our Latest Report on YMAB
Y-mAbs Therapeutics Price Performance
The stock has a market capitalization of $530.07 million, a P/E ratio of -24.65 and a beta of 0.69. The stock has a 50 day moving average price of $13.07 and a 200-day moving average price of $12.78.
Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its earnings results on Tuesday, May 7th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The company had revenue of $19.93 million for the quarter, compared to analysts' expectations of $22.06 million. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. Research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.
Insider Activity
In related news, insider Thomas Gad sold 35,000 shares of Y-mAbs Therapeutics stock in a transaction on Monday, June 10th. The shares were sold at an average price of $12.03, for a total value of $421,050.00. Following the transaction, the insider now directly owns 197,681 shares of the company's stock, valued at $2,378,102.43. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CFO Bo Kruse sold 31,371 shares of the business's stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $12.07, for a total transaction of $378,647.97. Following the transaction, the chief financial officer now owns 210,877 shares in the company, valued at approximately $2,545,285.39. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Thomas Gad sold 35,000 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $12.03, for a total value of $421,050.00. Following the completion of the sale, the insider now owns 197,681 shares of the company's stock, valued at approximately $2,378,102.43. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 99,444 shares of company stock valued at $1,203,925. 21.50% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Y-mAbs Therapeutics
Several hedge funds have recently made changes to their positions in YMAB. GSA Capital Partners LLP lifted its stake in Y-mAbs Therapeutics by 208.3% in the third quarter. GSA Capital Partners LLP now owns 137,299 shares of the company's stock worth $748,000 after acquiring an additional 92,765 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Y-mAbs Therapeutics in the 4th quarter worth about $562,000. Trexquant Investment LP boosted its stake in shares of Y-mAbs Therapeutics by 417.5% during the 3rd quarter. Trexquant Investment LP now owns 76,585 shares of the company's stock valued at $417,000 after purchasing an additional 61,785 shares in the last quarter. Los Angeles Capital Management LLC increased its position in shares of Y-mAbs Therapeutics by 17.3% during the fourth quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company's stock valued at $2,432,000 after buying an additional 52,610 shares during the period. Finally, Sapient Capital LLC purchased a new position in shares of Y-mAbs Therapeutics during the fourth quarter valued at about $298,000. 70.85% of the stock is owned by hedge funds and other institutional investors.
Y-mAbs Therapeutics Company Profile
(Get Free Report)
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
Recommended Stories
- Five stocks we like better than Y-mAbs Therapeutics
- Why Invest in 5G? How to Invest in 5G Stocks
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- What Are Dividend Achievers? An Introduction
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
→ The END of Joe Biden (From Banyan Hill Publishing) (Ad)
Should you invest $1,000 in Y-mAbs Therapeutics right now?
Before you consider Y-mAbs Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Y-mAbs Therapeutics wasn't on the list.
While Y-mAbs Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Investing Strategies To Help Grow Your Retirement Income
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
